We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $542M
1-Year Est. Return 206.64%
This Fund
S&P 500
This Quarter Est. Return
+6.19%
1 Year Est. Return
+206.64%
3 Year Est. Return
+724.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$271M
AUM Growth
+$8.22M
Cap. Flow
-$15.2M
Cap. Flow %
-5.61%
Top 10 Hldgs %
72.9%
Holding
39
New
14
Increased
6
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$13.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.36M
3
MRK icon
Merck
MRK
+$7.02M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$2.35M
5
AZN icon
AstraZeneca
AZN
+$1.65M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$26.1M
2
ARGX icon
argenx
ARGX
+$18.1M
3
NVO
Novo Nordisk
NVO
+$7.09M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$2.46M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.19M

Sector Composition

Rank Sector Weight
1 Healthcare 91.83%
2 Miscellaneous 8.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVO
1
Novo Nordisk
NVO
$199B
$51.1M 18.88%
642,110
-100,000
-13% -$7.09M
MRK icon
2
Merck
MRK
$366B
$35M 12.94%
329,200
+65,000
+25% +$7.02M
BIIB icon
3
Biogen
BIIB
$30.9B
$22.2M 8.22%
80,000
+50,000
+167% +$13.8M
KRTX
4
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$16.1M 5.96%
88,831
-10,436
-11% -$2M
ABBV icon
5
AbbVie
ABBV
$438B
$14.5M 5.35%
90,821
– –
ARGX icon
6
argenx
ARGX
$62B
$13.6M 5.01%
36,404
-48,800
-57% -$18.1M
MRNA icon
7
Moderna
MRNA
$55.4B
$13M 4.81%
84,719
+10,000
+13% +$1.65M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12.4B
$11.5M 4.26%
118,465
+90,248
+320% +$9.36M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$10.4M 3.83%
51,175
– –
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.84M 3.64%
404,615
-100,000
-20% -$2.19M
LLY icon
11
Eli Lilly
LLY
$1.01T
$9.25M 3.42%
26,928
-77,400
-74% -$26.1M
SRPT icon
12
CALL
Sarepta Therapeutics
SRPT
$2.22B
$8.27M 3.06%
+60,000
New +$7.78M
NVO
13
CALL
Novo Nordisk
NVO
$199B
$7.96M 2.94%
+100,000
New +$7.09M
AZN icon
14
AstraZeneca
AZN
$245B
$7.1M 2.62%
51,154
+12,274
+32% +$1.65M
KRTX
15
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.45M 2.01%
+30,000
New +$5.74M
BNTX icon
16
BioNTech
BNTX
$24.6B
$4.62M 1.71%
37,108
– –
NBIX icon
17
Neurocrine Biosciences
NBIX
$15.7B
$4.55M 1.68%
45,000
– –
RETA
18
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3.64M 1.34%
+40,000
New +$2.35M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$34.6B
$3.2M 1.18%
15,971
– –
TMO icon
20
Thermo Fisher Scientific
TMO
$222B
$2.93M 1.08%
5,088
– –
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.25M 0.83%
41,600
– –
VRTX icon
22
Vertex Pharmaceuticals
VRTX
$132B
$2.24M 0.83%
7,114
– –
VRNA
23
DELISTED
Verona Pharma
VRNA
$1.82M 0.67%
90,451
+50,500
+126% +$1.09M
CBAY
24
DELISTED
Cymabay Therapeutics
CBAY
$1.48M 0.55%
+169,277
New +$1.36M
CRL icon
25
Charles River Laboratories
CRL
$13.2B
$1.39M 0.52%
+6,905
New +$1.56M
1
2

Similar funds

CA
CV Advisors Aventura, Florida $542M AUM 24.89% 1-Year Est. Return
WCM
Westerly Capital Management San Francisco, California $542M AUM 48.48% 1-Year Est. Return
LI
Louisbourg Investments Dieppe, New Brunswick, Canada $542M AUM 21.44% 1-Year Est. Return
CWWM
Clear Wave Wealth Management Red Bank, New Jersey $541M AUM
FVCM
F&V Capital Management Boca Raton, Florida $542M AUM 46.38% 1-Year Est. Return
LI
Lafayette Investments Ashton, Maryland $542M AUM 22.5% 1-Year Est. Return
CCT
Chemung Canal Trust Elmira, New York $541M AUM 32.42% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

Artia Global Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Artia Global Partners held 39 positions worth $271M, up 3.1% from $262M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Artia Global Partners withdrew a net $15.2M in Q1 2023, closing 3 positions and reducing 7 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $2.46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Artia Global Partners opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $3.64M.

  • Artia Global Partners's largest Q1 2023 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 40,000 shares worth $3.64M.
  • Artia Global Partners added most to Biogen in Q1 2023, an estimated $13.8M increase.
  • Artia Global Partners's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $26.1M.
  • Artia Global Partners fully exited Prometheus Biosciences, Inc. Common Stock in Q1 2023, selling an estimated $2.46M.
  • Artia Global Partners's ten largest holdings make up 73% of its $271M portfolio in Q1 2023.
  • Artia Global Partners opened 14 new positions and closed 3 in Q1 2023.
  • Artia Global Partners's portfolio value rose 3.1% quarter-over-quarter to $271M.

Based on Artia Global Partners's 13F filing for Q1 2023, filed 15 May 2023.